Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
NCT07229716Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-9813 in pulmonary fibrosis (PF), sponsored by Hengrui Therapeutics. Primary endpoints: Maximum plasma concentration, Area under the concentration curve from time 0 to extrapolated infinite time and 2 more. Started Apr 2026; status: completed.
02
Drugs
HRS-9813
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT07229716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229716.